CLINICAL CRITERIA

该项目的目标是完善额颞叶变性（FTLD）的生前诊断， 通过将其与阿尔茨海默病（AD）区分开来，通过改善早期诊断， 区分具有泛素包涵体的患者与具有tau包涵体的患者。到第10年年底， PPG本项目将获得107例AD、131例FTD、67例SD、56例PNFA、43例CBD、30例 PSP、59例ALS和89例对照。将在37例AD、64例FTD、25例SD、23例PNFA、23例 23例PSP和27例ALS患者。通过探索这些人群的临床病理学相关性， 项目将实现以下目标：1.完善FTD、PNFA、SD、CBD和 PSP，以改善这些患者群体在生活中与AD患者的分离。这一目标将是 通过使用淀粉样蛋白成像与PIBURGH-化合物-B（PI B）来促进。此外，基因组学和 初步探索蛋白质组学作为鉴别诊断FTD、PNFA、SD、CBD和PSP的工具 彼此，彼此，彼此。2.探索具有临床痴呆评级的FTD患者的最早变化 (CDR)评分为0.5的患者和ALS患者（许多人将患有早期FTD）。这一目标将使用新的 通过临床和管理核心捕捉社会，情感和成像领域的范例 以及项目2、3和4。此外，基因组学和蛋白质组学将被探索作为早期癌症的潜在标志物。 FTD或FTD-ALS。3.根据病理学定义，确定最能预测FTLD-T与FTLD-U的综合征。的 将通过分析通过临床和管理核心和项目2收集的数据来实现目标 和3.此外，将在这些人群中探索基因组和蛋白质组学特征。

The project's goal is to refine antemortem diagnosis of frontotemporallobar degeneration (FTLD) and related disorders by distinguishing them from Alzheimer's disease (AD), by improving early diagnosis and by differentiating patients with ubiquitin inclusions from those with tau inclusions. By the end of year 10 of the PPG this project will have obtained novel assessment on 107 AD, 131 FTD, 67 SD, 56 PNFA, 43 CBD, 30 PSP, 59 ALS, and 89 controls. Neuropathology will be completed in 37 AD, 64 FTD, 25 SD, 23 PNFA, 23 CBD, 23 PSP and 27 ALS patients. By exploring clinical pathological correlates in these populations the project will accomplish the following aims: 1. Refine diagnostic approaches to FTD, PNFA, SD, CBD, and PSP in order to improve separation of these patient groups during life from patients with AD. This aim will be facilitated by the use of amyloid imaging with the Pittsburgh-compound-B (PIB). Also, genomics and proteomics will be preliminarily explored as tools for differential diagnosis of FTD, PNFA, SD, CBD and PSP from each other, and from AD. 2. Explore the earliest changes in FTD patients with a clinical dementia rating (CDR) score of 0.5, and ALS patients (many will have early FTD). This aim will be tested using novel paradigms that capture social, emotional and imaging domains through the Clinical and Administrative Core and in projects 2, 3 and 4. Also, genomics and proteomics will be explored as potential markers of early FTD or FTD-ALS. 3. Identify syndromes that best predict FTLD-T vs. FTLD-U as defined at pathology. The aim will be performed by analyzing data collected through the Clinical and Administrative Core and projects 2 and 3. Also, genomic and proteomic profiles will be explored in these populations.